Regeneron Pharmaceuticals Current Ratio Growth & History (REGN)
Regeneron Pharmaceuticals's current ratio was 4.13 for fiscal 2025.
View full Regeneron Pharmaceuticals company overviewRegeneron Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 4.13 | −0.61 | −12.80% |
| 2024 | 2024-12-31 | 4.73 | −0.96 | −16.85% |
| 2023 | 2023-12-31 | 5.69 | 0.63 | +12.53% |
| 2022 | 2022-12-31 | 5.06 | 1.49 | +41.88% |
| 2021 | 2021-12-31 | 3.56 | −0.06 | −1.70% |
| 2020 | 2020-12-31 | 3.63 | −0.04 | −1.15% |
| 2019 | 2019-12-31 | 3.67 | −0.80 | −17.93% |
| 2018 | 2018-12-31 | 4.47 | 0.65 | +17.06% |
| 2017 | 2017-12-31 | 3.82 | 1.26 | +49.04% |
| 2016 | 2016-12-31 | 2.56 | −1.03 | −28.72% |
| 2015 | 2015-12-31 | 3.59 | 0.41 | +12.85% |
| 2014 | 2014-12-31 | 3.18 | −2.83 | −47.04% |
| 2013 | 2013-12-31 | 6.01 | −1.36 | −18.45% |
| 2012 | 2012-12-31 | 7.37 | 2.88 | +64.22% |
| 2011 | 2011-12-31 | 4.49 | 1.21 | +36.93% |
| 2010 | 2010-12-31 | 3.28 | −1.27 | −27.88% |
| 2009 | 2009-12-31 | 4.55 | — | — |
Regeneron Pharmaceuticals quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.34 | −1.26 | −27.46% |
| Q1 2026 | 2026-03-31 | 3.57 | −1.36 | −27.64% |
| Q4 2025 | 2025-12-31 | 4.13 | −0.61 | −12.80% |
| Q3 2025 | 2025-09-30 | 4.06 | −1.22 | −23.06% |
| Q2 2025 | 2025-06-30 | 4.60 | −0.84 | −15.46% |
| Q1 2025 | 2025-03-31 | 4.93 | −0.34 | −6.51% |
| Q4 2024 | 2024-12-31 | 4.73 | −0.96 | −16.85% |
| Q3 2024 | 2024-09-30 | 5.28 | 0.10 | +1.98% |
| Q2 2024 | 2024-06-30 | 5.44 | −0.01 | −0.23% |
| Q1 2024 | 2024-03-31 | 5.27 | −0.18 | −3.38% |
| Q4 2023 | 2023-12-31 | 5.69 | 0.63 | +12.53% |
| Q3 2023 | 2023-09-30 | 5.18 | −0.18 | −3.36% |
| Q2 2023 | 2023-06-30 | 5.45 | 0.33 | +6.50% |
| Q1 2023 | 2023-03-31 | 5.45 | 0.70 | +14.67% |
| Q4 2022 | 2022-12-31 | 5.06 | 1.49 | +41.88% |
| Q3 2022 | 2022-09-30 | 5.36 | 1.65 | +44.51% |
| Q2 2022 | 2022-06-30 | 5.12 | 1.55 | +43.24% |
| Q1 2022 | 2022-03-31 | 4.76 | 1.63 | +52.22% |
| Q4 2021 | 2021-12-31 | 3.56 | −0.06 | −1.70% |
| Q3 2021 | 2021-09-30 | 3.71 | −0.18 | −4.71% |
| Q2 2021 | 2021-06-30 | 3.57 | 1.45 | +68.32% |
| Q1 2021 | 2021-03-31 | 3.12 | −1.08 | −25.70% |
| Q4 2020 | 2020-12-31 | 3.63 | −0.04 | −1.15% |
| Q3 2020 | 2020-09-30 | 3.89 | −0.14 | −3.36% |
| Q2 2020 | 2020-06-30 | 2.12 | −1.76 | −45.32% |
| Q1 2020 | 2020-03-31 | 4.21 | −0.38 | −8.25% |
| Q4 2019 | 2019-12-31 | 3.67 | −0.80 | −17.93% |
| Q3 2019 | 2019-09-30 | 4.03 | −0.01 | −0.22% |
| Q2 2019 | 2019-06-30 | 3.88 | 0.27 | +7.34% |
| Q1 2019 | 2019-03-31 | 4.58 | 0.99 | +27.67% |
| Q4 2018 | 2018-12-31 | 4.47 | 0.65 | +17.06% |
| Q3 2018 | 2018-09-30 | 4.04 | 0.40 | +11.11% |
| Q2 2018 | 2018-06-30 | 3.62 | −0.13 | −3.58% |
| Q1 2018 | 2018-03-31 | 3.59 | 0.79 | +28.02% |
| Q4 2017 | 2017-12-31 | 3.82 | 1.26 | +49.04% |
| Q3 2017 | 2017-09-30 | 3.63 | −0.01 | −0.30% |
| Q2 2017 | 2017-06-30 | 3.75 | 0.38 | +11.23% |
| Q1 2017 | 2017-03-31 | 2.80 | −0.60 | −17.68% |
| Q4 2016 | 2016-12-31 | 2.56 | −1.03 | −28.72% |
| Q3 2016 | 2016-09-30 | 3.64 | 0.00 | +0.07% |
| Q2 2016 | 2016-06-30 | 3.37 | −0.42 | −11.15% |
| Q1 2016 | 2016-03-31 | 3.41 | −0.90 | −20.95% |
| Q4 2015 | 2015-12-31 | 3.59 | 0.41 | +12.85% |
| Q3 2015 | 2015-09-30 | 3.64 | −1.72 | −32.14% |
| Q2 2015 | 2015-06-30 | 3.80 | −1.66 | −30.45% |
| Q1 2015 | 2015-03-31 | 4.31 | −1.82 | −29.73% |
| Q4 2014 | 2014-12-31 | 3.18 | −2.83 | −47.04% |
| Q3 2014 | 2014-09-30 | 5.36 | −0.72 | −11.78% |
| Q2 2014 | 2014-06-30 | 5.46 | −2.20 | −28.77% |
| Q1 2014 | 2014-03-31 | 6.13 | −0.49 | −7.45% |
| Q4 2013 | 2013-12-31 | 6.01 | −1.36 | −18.45% |
| Q3 2013 | 2013-09-30 | 6.08 | 0.77 | +14.47% |
| Q2 2013 | 2013-06-30 | 7.66 | 3.46 | +82.49% |
| Q1 2013 | 2013-03-31 | 6.63 | 2.28 | +52.51% |
| Q4 2012 | 2012-12-31 | 7.37 | 2.88 | +64.22% |
| Q3 2012 | 2012-09-30 | 5.31 | 2.76 | +108.25% |
| Q2 2012 | 2012-06-30 | 4.20 | 1.16 | +38.02% |
| Q1 2012 | 2012-03-31 | 4.35 | 1.45 | +49.85% |
| Q4 2011 | 2011-12-31 | 4.49 | 1.21 | +36.93% |
| Q3 2011 | 2011-09-30 | 2.55 | −1.75 | −40.70% |
| Q2 2011 | 2011-06-30 | 3.04 | −0.45 | −12.94% |
| Q1 2011 | 2011-03-31 | 2.90 | — | — |
| Q4 2010 | 2010-12-31 | 3.28 | −1.27 | −27.88% |
| Q3 2010 | 2010-09-30 | 4.30 | — | — |
| Q2 2010 | 2010-06-30 | 3.49 | — | — |
| Q4 2009 | 2009-12-31 | 4.55 | — | — |
Regeneron Pharmaceuticals current ratio trends
Over the last five fiscal years, Regeneron Pharmaceuticals's current ratio increased from 3.63 to 4.13, a change of 0.50. The latest reported quarter, Q2 2026, shows 3.34.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regeneron Pharmaceuticals source filings ↗